SEC Form 4 · accession 0001193125-26-300921
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Claire Fraser
Director
Period of report
Jul 8, 2026
Accepted (ET)
Jul 10, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001609809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $7.14 | Jul 8, 2026 | A | 6,500 | A | — | Jul 7, 2036 | Common Stock | 6,500 | 6,500 | D |
Explanation of responses
- F1The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.